Abstract
Exposure to reactive oxygen species (ROS) (e.g., peroxide) was shown to induce expression of the PA5471 gene, which was previously shown to be required for antimicrobial induction of the MexXY components of the MexXY-OprM multidrug efflux system and aminoglycoside resistance determinant in Pseudomonas aeruginosa. mexXY was also induced by peroxide exposure, and this too was PA5471 dependent. The prospect of ROS promoting mexXY expression and aminoglycoside resistance recalls P. aeruginosa infection of the chronically inflamed lungs of cystic fibrosis (CF) patients, where the organism is exposed to ROS and where MexXY-OprM predominates as the mechanism of aminoglycoside resistance. While ROS did not enhance aminoglycoside resistance in vitro, long-term (8-day) exposure of P. aeruginosa to peroxide (mimicking chronic in vivo ROS exposure) increased aminoglycoside resistance frequency, dependent upon PA5471 and mexXY. This enhanced resistance frequency was also seen in a mutant strain overexpressing PA5471, in the absence of peroxide, suggesting that induction of PA5471 by peroxide was key to peroxide enhancement of aminoglycoside resistance frequency. Resistant mutants selected following peroxide exposure were typically pan-aminoglycoside-resistant, with mexXY generally required for this resistance. Moreover, PA5471 was required for mexXY expression and aminoglycoside resistance in these as well as several CF isolates examined.
Multidrug efflux systems of the three-component resistance-nodulation-division (RND) family contribute significantly to intrinsic and acquired resistance to antimicrobials in a number of Gram-negative bacteria (39, 41). Pseudomonas aeruginosa, an opportunistic human pathogen (28), expresses several RND-type multidrug efflux systems, of which four, MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM, are reported to be significant determinants of multidrug resistance in lab and clinical isolates (38). MexXY-OprM is somewhat unique in P. aeruginosa in that the mexXY operon is induced upon exposure to many of the antibiotics that this efflux system exports (31). Still, only those agents known to target the ribosome promote mexXY expression (26, 31, 34), and this is compromised by so-called ribosome protection mechanisms (26), suggesting that the MexXY-OprM efflux system is recruited in response to ribosome disruption or defects in translation and not antibiotics per se. Consistent with this, mutations in fmt (encoding a methionyl-tRNA-formyltransferase) and folD (involved in folate biosynthesis and production of the formyl group added to initiator methionine), which are expected to negatively affect protein synthesis, increase expression of mexXY (6). Upregulation of mexXY by antimicrobials or fmt/folD mutations is dependent upon a gene, PA5471, encoding a conserved hypothetical protein whose expression is also promoted by ribosome-disrupting antimicrobials (34) and by fmt/folD mutations (6). Despite this primary link to translation disruption, the MexXY-OprM efflux system is a significant determinant of resistance to antimicrobials in clinical isolates, particularly aminoglycosides (19, 40, 52) but also β-lactams (3, 19, 23, 37, 51). Indeed, while it is uncommon as a mechanism of aminoglycoside resistance in most clinical strains of P. aeruginosa, MexXY-OprM is the predominant mechanism of resistance to these agents in cystic fibrosis (CF) isolates (19, 40, 52). Consistent with mexXY expression being commonplace in CF lung isolates. mexX is induced in vitro upon exposure of P. aeruginosa to human airway epithelial cells (17) and mexY shows enhanced expression in this organism in the CF lung (DNA array performed on RNA isolated from sputum) (48).
Recent transcriptome studies revealed that PA5471 is substantially upregulated in P. aeruginosa cells subjected to oxidative stress imposed by disinfectants such as peroxide (H2O2) (7) and peracetic acid (8), although mexXY expression was not reported (only highly up-/downregulated genes were reported). Intriguingly, the CF lung is rich in reactive oxygen species (ROS) (11) owing to the chronic inflammation that is apparently the result of the CF transmembrane conductance regulator (CFTR) defect that characterizes this disease and of chronic P. aeruginosa infection (27, 45). Given that MexXY-mediated efflux is the most common mechanism of aminoglycoside resistance in P. aeruginosa CF isolates (43), the implication is that ROS may be promoting the development of aminoglycoside resistance in CF lung isolates, mediated by PA5471 and MexXY. Thus, the impact of ROS (H2O2) on mexXY expression and development of MexXY-OprM-dependent aminoglycoside resistance in vitro was examined.
MATERIALS AND METHODS
Bacterial strains and plasmids.
The bacterial strains and plasmids used in this study are listed in Table 1. Bacterial cells were cultured in Luria broth (L broth) and on Luria agar with antibiotics, as necessary, at 37°C. Plasmid pEX18Tc and its derivatives were maintained in Escherichia coli with 10 μg/ml of tetracycline. ΔmexXY and ΔPA5471 derivatives of P. aeruginosa were constructed by mobilizing pEX18Tc::ΔmexXY (pCSV05-01) and pEX18Tc::ΔPA5471 (pYM008), respectively, into P. aeruginosa from E. coli S17-1 as described previously (5) with modifications. Briefly, 700 μl of plasmid-carrying E. coli S17-1 (log phase, cultured at 37°C) was mixed with 300 μl of P. aeruginosa (stationary phase, cultured at 42°C) in a microcentrifuge tube and centrifuged, and the pellet was resuspended in 100 μl of L broth and spotted onto the center of an L-agar plate. Following incubation at 37°C for 6 h, bacteria were recovered from the L-agar plate in 100 μl L broth, and P. aeruginosa transconjugants harboring chromosomal inserts of the deletion vectors were selected on L-agar plates containing tetracycline (75 μg/ml) and chloramphenicol (5 μg/ml; to counterselect E. coli S17-1). These were subsequently streaked onto L agar containing sucrose (10% [wt/vol]) as before (5), with sucrose-resistant colonies screened for the appropriate deletion using colony PCR.
TABLE 1.
Bacterial strains and plasmids
| Strain or plasmid | Relevant characteristicsa | Reference |
|---|---|---|
| E. coli | ||
| DH5α | φ80d lacZΔM15 endA1 recA1 hsdR17 (rK− mK+) supE44 thi-1 gyrA96 relA1 F− Δ(lacZYA-argF)U169 | 1 |
| S17-1 | thi pro hsdR recA Tra+ | 46 |
| P. aeruginosa | ||
| K767 | PAO1 prototroph | 30 |
| K1525 | K767 ΔmexXY | 14 |
| K2413 | K767 ΔPA5471 | 34 |
| K2415 | K767 ΔmexZ | 34 |
| K2416 | K2415 ΔPA5471 | 34 |
| K2817 | K767 PA5471.1Q3Am (PA5471++) | 33 |
| K2965 | Amikacin-resistant derivative of K767 selected following an 8-day exposure to H2O2 | This study |
| K2966 | Amikacin-resistant derivative of K767 selected following an 8-day exposure to H2O2 | This study |
| K2967 | Amikacin-resistant derivative of K767 selected following an 8-day exposure to H2O2 | This study |
| K2968 | Amikacin-resistant derivative of K767 selected following an 8-day exposure to H2O2 | This study |
| K2969 | K2965 ΔmexXY | This study |
| K2970 | K2966 ΔmexXY | This study |
| K2971 | K2867 ΔmexXY | This study |
| K2972 | K2968 ΔmexXY | This study |
| K2973 | K2966 ΔPA5471 | This study |
| K2974 | K2967 ΔPA5471 | This study |
| K2975 | K2968 ΔPA5471 | This study |
| K2152 | CF isolate | 47 |
| Κ2427 | K2152 ΔPA5471 | This study |
| Κ2164 | K2152 ΔmexXY | 47 |
| K2153 | CF isolate | 47 |
| Κ2428 | K2153 ΔPA5471 | This study |
| Κ2165 | K2153 ΔmexXY | 47 |
| K2160 | CF isolate | 47 |
| Κ2430 | K2160 ΔPA5471 | This study |
| Κ2168 | K2160 ΔmexXY | 47 |
| K2161 | CF isolate | 47 |
| K2431 | K2161 ΔPA5471 | This study |
| Κ2169 | K2161 ΔmexXY | 47 |
| K2158 | CF isolate | 47 |
| Κ2432 | K2158 ΔPA5471 | This study |
| Κ2171 | K2158 ΔmexXY | 47 |
| K2163 | CF isolate | 47 |
| Κ2433 | K2163 ΔPA5471 | This study |
| Κ2172 | K2163 ΔmexXY | 47 |
| Plasmids | ||
| pEX18Tc | Gene-replacement vector; sacB Tcr | 21 |
| pYM008 | pEX18Tc::ΔPA5471 | 34 |
| pCSV05 | pEX18Tc::ΔmexXY | 14 |
Tcr, tetracycline resistance.
Colony PCR.
To identify ΔmexXY and ΔPA5471 derivatives of P. aeruginosa, single colonies were recovered from sucrose plates and resuspended in 30 μl sterile distilled H2O, which was then heated for 5 min at 95°C and centrifuged for 1 min at 13,000 rpm. The mexXY operon and PA5471 were amplified with primer pairs mexXY-KO-Scr-F (5′-CACCAGGAAGAACAGCGGTA-3′) and mexXY-KO-Scr-R (5′-CAGA-TCATAAGGATATGTTA-3′), and PA5471-KO-Scr-F (5′-CCTGGGAAGGCTATACCAACG-3′) and PA5471-KO-Scr-R (5′-GCTTCATCGGCACCATCAT-3′), respectively, in a 10-μl PCR mixture containing 2 μl of colony lysate, 0.6 μM each primer, 0.2 mM each deoxynucleoside triphosphate, 0.5 U of Taq Polymerase (New England BioLabs, Ltd., Pickering, Ontario, Canada), 1× ThermoPol buffer and 5% (vol/vol) dimethyl sulfoxide (DMSO). The mixture was heated for 5 min at 95°C, followed by 30 cycles of 0.5 min at 95°C, 0.5 min at 51°C (mexXY) or 60°C (PA5471), and 5 min (mexXY) or 3.5 min (PA5471) at 72°C, finishing with 7 min at 72°C. Products were then visualized on agarose gels.
Selection of aminoglycoside-resistant mutants following exposure to H2O2.
Overnight cultures (in L broth) of various P. aeruginosa strains were diluted 1:49 in fresh L broth and grown for 2 h. H2O2 (1 mM final concentration) was then added three times at 2-hour intervals, after which cultures were allowed to recover overnight. This was repeated daily over 8 days, at which time serial dilutions were plated on L agar (to enumerate total cell numbers) and L agar supplemented with amikacin (at 2.5× MIC) or tobramycin (at 1× MIC) (to enumerate numbers of amikacin- or tobramycin-resistant bacteria and to calculate the resistance frequency). Eight-day unexposed P. aeruginosa controls were processed in parallel. Randomly selected amikacin-resistant colonies were subsequently picked, passaged eight times on L-agar plates, and then assessed for resistance to amikacin and to additional aminoglycosides. Stable pan-aminoglycoside-resistant mutants were saved for further study. In some experiments, aminoglycoside-resistant mutants were recovered and resistance frequency determined following overnight growth (16 h) only.
DNA methods.
Standard protocols were generally used for restriction endonuclease digestion, ligation, transformation, plasmid isolation, and agarose gel electrophoresis, as described by Sambrook and Russell (44). Plasmid DNAs were also prepared from E. coli or P. aeruginosa using a GeneJET Plasmid Miniprep kit (Fermentas Canada Inc., Burlington, Ontario, Canada) or QIAfilter Plasmid Midikit (Qiagen Inc., Mississauga, Ontario, Canada) according to the protocols provided by the manufacturer. Chromosomal DNA of P. aeruginosa was extracted using a DNeasy Blood & Tissue kit (Qiagen) according to the protocol provided by the manufacturer. PCR products were purified using a Wizard SV gel and PCR clean-up system (Fisher Scientific, Ltd., Nepean, Ontario, Canada) and, when cloned, sequenced to verify that no mutations were introduced during PCR. Competent P. aeruginosa (9) and E. coli (24) cells were prepared as described previously. Oligonucleotide synthesis was carried out by Integrated DNA Technologies (Coralville, IA), and nucleotide sequencing was carried out by ACGT Corp. (Toronto, Ontario, Canada) using universal and custom primers.
Susceptibility testing.
The antimicrobial susceptibilities of various P. aeruginosa strains were assessed in 96-well microtiter plates using 2-fold serial dilutions as described previously (27).
RT-PCR.
Total bacterial RNA was isolated from log-phase P. aeruginosa L-broth cultures (with and without 1 mM H2O2), using a High Pure RNA isolation kit (Roche Canada, Mississauga, Ontario, Canada), Turbo DNA-free DNase (Applied Biosystems Canada, Streetsville, Ontario, Canada), and a protocol provided by the manufacturer (Roche). The reverse transcription-PCR (RT-PCR) was performed with ca. 50 ng RNA using the Qiagen one-step RT-PCR kit according to a protocol provided by the manufacturer. Primers and reaction conditions for amplification of rpoD, PA5471, and mexX have been described previously (34). RT-free control reactions were carried out to ensure that there was no DNA contamination of RNA preparations.
PCR amplification of mexZ, mexXY, and PA5471.1.
To screen various pan-aminoglycoside-resistant P. aeruginosa strains for mutations in mexZ (including its promoter region), mexXY, and PA5471.1, the genes were amplified from the chromosome prior to sequencing. The mexZ gene, including the entirety of the mexZ-mexXY intergenic region, was amplified with primers mexZ-295-F (5′-ACGATCACGCCGACCTCG-3′) and mexZ-80-R (5′-GAGG-AAGACGCCCAGCGGCT-3′) in a 50-μl PCR mixture formulated as before for PA5471 (34), except that Phusion high-fidelity DNA polymerase (New England BioLabs, Ltd., Pickering, Ontario, Canada) was used (1 U) in 1× Phusion GC buffer and MgCl2 was omitted. The mixture was heated for 0.5 min at 98°C, followed by 30 cycles of 0.5 min at 98°C, 0.5 min at 65°C, and 0.3 min at 72°C, before finishing with 7 min at 72°C. The mexXY operon was amplified in two overlapping PCR products using primers mexXY-1-F (5′-TGAGTTGCGGTGCCCTTT-3′) and mexXY-1-R (5′-CGAACGCCGAGGTGTCA-TA-3′) for fragment 1 and primers mexXY-2-F (5′-AGCGAGTACGGCTTCGTCT-3′) and mexXY-2-R (5′-GGTCGGTGAACTGCTGTTG-3′) for fragment 2. Both fragments were amplified in a 50-μl PCR mixture formulated as described above for mexZ with the exception that 5% (vol/vol) DMSO was included and the first 72°C incubation was for 1 min. Amplification of PA5471.1 was achieved as described previously (33).
RESULTS
Peroxide induction of mexXY dependent on PA5471.
Transcriptome analysis has revealed that exposure of P. aeruginosa to oxidative stress-promoting agents such as peroxide (7) and peracetic acid (8) induces expression of the PA5471 gene, which is required for induction of the mexXY multidrug efflux operon in response to ribosome-targeting antimicrobials (34). Using RT-PCR, peroxide induction of PA5471 was confirmed (Fig. 1 A lane 2 [cf. lane 1]). Given that ribosome-targeting-drug inducibility of mexXY follows from induction of PA5471 by the same drugs (34), it was of interest to examine whether mexXY was also peroxide inducible. As seen in Fig. 1B, lane 2 (cf. lane 1), this efflux operon was indeed induced by peroxide. Moreover, this induction was dependent on PA5471, being lost in the ΔPA5471 mutant K2413 (Fig. 1B, lane 4 [cf. lane 3]). Despite the induction of mexXY by peroxide, however, the MexXY-OprM efflux system did not contribute to peroxide resistance (the peroxide MIC for the ΔmexXY strain K1525 remained the same as that for wild-type parent strain K767, 2 mM). The mechanism by which peroxide induces PA5471 (and subsequently mexXY) expression is as yet unresolved but may involve the same transcriptional attenuation mechanism that explains antibiotic inducibility of PA5471 (i.e., peroxide may interfere with ribosome function, leading to loss of attenuation and thus read-through transcription of PA5471) (33).
FIG. 1.

(I) Influence of H2O2 on expression of PA5471 (A) and mexXY (B) in P. aeruginosa. Wild-type P. aeruginosa strain K767 (lanes 1 and 2) and its ΔPA5471 derivative K2413 (lanes 3 and 4) were grown to mid-log phase and cultured without or with 1 mM H2O2 for 30 min, and PA5471 or mexXY expression was assessed using RT-PCR. (II) Expression of rpoD was also assessed and served as an internal control that ensured that equal amounts of RNA were employed in all of the RT-PCRs shown. The PCR portion of the reactions was carried out for 28 (PA5471), 32 (mexX), or 20 (rpoD) cycles (upper panels of I or II) and for 30, (PA5471), 34 (mexX), or 22 (rpoD) cycles (lower panels of I or II).
Peroxide treatment enhances recovery of aminoglycoside-resistant mutants of PAO1 dependent on PA5471 and MexXY.
Given the observation that oxidative stress enhances expression of the MexXY components of a multidrug efflux system, the possibility existed that it might positively influence MexXY-OprM-mediated antimicrobial resistance. The presence of half the MIC of peroxide did not, however, influence the resistance of wild-type P. aeruginosa PAO1 strain K767 to any MexXY-OprM antimicrobial substrate tested (e.g., aminoglycosides, erythromycin, tetracycline, and chloramphenicol), presumably because these antimicrobials themselves induce mexXY expression (31) (i.e., peroxide induction of mexXY and its subsequent effect on antimicrobial resistance are “masked” by the positive impact that the antimicrobials have on their own resistance by virtue of their induction of the efflux genes in the MIC assay). Still, ROS induction of mexXY suggested that the MexXY-OprM efflux system likely plays a positive role in an oxidative stress response such that peroxide exposure over time might provide a selective pressure for mexXY-expressing antimicrobial-resistant mutants. It is, for example, interesting to note that MexXY-OprM-mediated efflux is the predominant mechanism of aminoglycoside resistance in P. aeruginosa isolates recovered from the lungs of cystic fibrosis (CF) patients (40) an environment noted for its richness in ROS (25, 43). The implication here is that ROS may be promoting the development of aminoglycoside resistance in CF lung isolates mediated by PA5471 and MexXY-OprM. In a modest attempt to mimic chronic exposure of P. aeruginosa to ROS in vitro and assess the impact on mexXY and aminoglycoside resistance, various strains of P. aeruginosa were exposed to three doses of half the MIC of peroxide daily over 8 days and the impact on aminoglycoside resistance frequency assessed, using amikacin and tobramycin as representative aminoglycosides that are commonly used to treat P. aeruginosa CF lung infections (4, 35, 49). Chronic in vitro exposure of wild-type P. aeruginosa (K767) to peroxide produced a 4-fold increase in amikacin resistance frequency relative to that of an ROS-free control (at 2.5× MIC) (Table 2). Peroxide exposure for 1 day did not promote any increase in amikacin resistance frequency in P. aeruginosa K767 (data not shown), indicating that longer-term exposure was necessary for this effect. This peroxide-promoted enhancement of aminoglycoside resistance frequency was dependent on both mexXY (amikacin-resistant mutants were not selectable in the ΔmexXY strain K1525) and PA5471 (peroxide had no effect on amikacin resistance frequency in the ΔPA5471 strain K2413) (Table 2). This indicated that MexXY was absolutely required for resistance to amikacin at 2.5× MIC and that peroxide-inducible PA5471 was required for peroxide enhancement of the amikacin resistance frequency. Intriguingly, overexpression of PA5471 alone (owing to a chromosomal mutation in the PA5471.1 open reading frame [ORF] upstream of PA5471 [33]) was able to enhance amikacin resistance frequency 8-fold in the absence of peroxide (see K2817 in Table 2). This enhancement of resistance frequency was seen following as little as 16 h of cultivation of K2817 (data not shown). These data suggested that the positive effect of peroxide on amikacin resistance frequency resulted from peroxide promotion of PA5471 expression and not some other impact of peroxide. Similar results were obtained for tobramycin (data not shown).
TABLE 2.
PA5471-dependent peroxide (H2O2) enhancement of amikacin resistance frequency in P. aeruginosaa
| Strain | Relevant phenotype | Peroxide | Amikacin resistance frequency | Fold changed |
|---|---|---|---|---|
| K767 | Wild type | − | 7.8E−6 | |
| + | 2.6E−5 | 3.3 (4.6 ± 1.5) | ||
| K2413 | PA547− | − | 1.0E−6 | |
| + | 1.0E−6 | 1.0 (1.2 ± 0.1) | ||
| K1525 | MexXY− | − | —c | |
| + | — | |||
| K2415 | MexZ− (MexXY++) | − | 3.2E−5 | |
| + | 2.7E−4 | 8.4 (6.7 ± 1.6) | ||
| K2416 | MexZ− (MexXY++) | − | 4.3E−5 | |
| PA547− | + | 5.8E−5 | 1.3 (1.5 ± 0.1) | |
| K767 | PA5471.1WT (PA5471+)b | − | 6.4E−6 | |
| K2817 | PA5471.1Q3Am (PA5471++)b | − | 5.4E−5 | 8.4 (8.0 ± 0.6) |
The indicated P. aeruginosa strains were exposed (+) or not (−) to H2O2 (1 mM) over 8 days, mutants resistant to amikacin (2.5× MIC for each strain) were selected and enumerated, and the resistance frequency was determined. Results of a representative experiment is shown.
The relative PA5471 level is in parentheses (+, expressed at wild-type levels; ++, hyperexpressed). PA5471 hyperexpression was achieved via introduction of a nonsense mutation (Q3Am) into the PA5471.1 ORF in generating strain K2817. PA5471.1WT, wild-type PA5471.1.
—, no mutants capable of growth at 2.5× MIC were recovered.
Except for strains K767 (second entry only) and K2817, the fold change in amikacin resistance frequency in peroxide-treated versus untreated P. aeruginosa is shown. For strains K767 (second entry) and K2817, the fold change in amikacin resistance frequency in P. aeruginosa hyperexpressing versus not hyperexpressing PA5471 is shown. Numbers in parentheses represent the mean ± standard deviation from three independent experiments.
MexXY-dependent pan-aminoglycoside resistance in peroxide-exposed wild-type P. aeruginosa.
Ten randomly selected amikacin-resistant peroxide-exposed mutants derived from wild-type P. aeruginosa K767 were screened for resistance to additional aminoglycosides. All showed enhanced resistance to the four aminoglycosides tested (Table 3), indicating that amikacin readily selected pan-aminoglycoside-resistant mutants. To assess the involvement of MexXY in this resistance, four mutants were examined for mexXY expression using RT-PCR. Two mutants (K2966 and K2968) (Fig. 2, lanes 2 and 4) showed elevated mexXY expression relative to that in K767, while two (K2965 and K2967) (Fig. 2, lanes 3 and 5) did not. Neither of the mexXY-expressing mutants harbored a mutation in mexZ, encoding the repressor of the mexXY operon (32), or the mexZ-mexXY intergenic region. Consistent with MexXY being responsible for the pan-aminoglycoside resistance of K2966 and K2968, deletion of mexXY from these mutants fully reversed resistance, to levels seen for a ΔmexXY derivative of K767, K1525 (Table 4). Interestingly, deletion of mexXY from K2967 also fully reversed resistance, to levels seen for K1525 (Table 4). Thus, despite no overt increase in mexXY expression in this mutant, MexXY-OprM was required for its pan-aminoglycoside-resistant phenotype. No mutations, however, were observed in the mexXY genes of K2967 (a missense mutation in mexY has previously been linked to a modest [2-fold] increase in aminoglycoside resistance [50]).
TABLE 3.
Pan-aminoglycoside resistance of amikacin-resistant mutants of P. aeruginosa selected following an 8-day peroxide exposurea
| Strainb | MIC (μg/ml)c |
|||
|---|---|---|---|---|
| AMI | TOB | GEN | PAR | |
| K767 (wild type) | 4 | 1 | 4 | 256 |
| AMIr-T1 (K2965) | 16 | 4 | 8 | 512 |
| AMIr-T2 | 8 | 2 | 4 | ≥2,048 |
| AMIr-T3 | 8 | 2 | 8 | 1,024 |
| AMIr-T4 | 8 | 4 | 8 | ≥2,048 |
| AMIr-T5 (K2966) | 16 | 2 | 8 | ≥2,048 |
| AMIr-T6 | 8 | 4 | 8 | 1,024 |
| AMIr-T7 (K2967) | 8 | 4 | 8 | 1,024 |
| AMIr-T8 | 8 | 2 | 8 | ≥2,048 |
| AMIr-T9 | ≥16 | 2 | 8 | ≥2,048 |
| AMIr-T10 (K2968) | 8 | 2 | 8 | 2,048 |
Wild-type P. aeruginosa K767 was exposed to peroxide (half the MIC; 1 mM) for 8 days and mutants resistant to 2.5× MIC for amikacin selected and screened for resistance to additional aminoglycosides. Results for 10 randomly selected mutants are shown.
Four mutants that were studied in greater detail are noted with strain designations in parentheses.
AMI, amikacin; TOB, tobramycin; GEN, gentamicin; PAR, paromomycin.
FIG. 2.

mexXY expression in pan-aminoglycoside-resistant P. aeruginosa selected on amikacin following exposure to H2O2. Expression was assessed in K767 (lane 1) and four randomly selected amikacin (and pan-aminoglycoside)-resistant mutants (lane 2, K2966; lane 3, K2965; lane 4, K2968; lane 5, K2967) using RT-PCR. Expression of rpoD was also assessed and served as an internal control that ensured that equal amounts of RNA were employed in all of the RT-PCRs shown. The PCR portion the RT-PCRs was carried out for 32 (mexX) or 20 (rpoD) cycles (upper panels) and for 34 (mexX) or 22 (rpoD) cycles (lower panels).
TABLE 4.
MexXY-dependent pan-aminoglycoside resistance of amikacin-resistant mutants derived from peroxide-exposed P. aeruginosa PAO1 strain K767a
| Strain | MexXYb | MIC (μg/ml)c |
|||
|---|---|---|---|---|---|
| AMI | TOB | GEN | PAR | ||
| K767 | + | 4 | 1 | 4 | 256 |
| K1525 | − | 1-2 | 0.5-1 | 1-2 | 32 |
| K2965d | + | 16 | 4 | 8 | 512 |
| K2969 | − | 4 | 4 | 4 | 32 |
| K2967d | + | 8 | 4 | 8 | 1,024 |
| K2971 | − | 2 | 1 | 1 | 32 |
| K2966d | + | 16 | 2 | 8 | ≥2,048 |
| K2970 | − | 2 | 1 | 1 | 64 |
| K2968d | + | 8 | 2 | 8 | 2,048 |
| K2972 | − | 2 | 1 | 1-2 | 32 |
The mexXY genes were deleted from four representative pan-aminoglycoside-resistant mutants (Table 3) and the impact on aminoglycoside susceptibility assessed. Data for wild-type strain K767 and its ΔPA5471 derivative K2413 are shown for comparison purposes.
MexXY status of the indicated strains. +, present; −, absent owing to deletion.
AMI, amikacin; TOB, tobramycin; GEN, gentamicin; PAR, paromomycin.
Mutant strain selected on amikacin.
PA5471-dependent MexXY-mediated aminoglycoside resistance in peroxide-exposed P. aeruginosa and in CF isolates.
PA5471 is required for antimicrobial (38) and peroxide (see above) induction of mexXY expression. It is unclear, however, whether it is required for mexXY expression in pan-aminoglycoside-resistant mutants recovered following peroxide exposure in vitro or in isolates recovered from the CF lung. To assess this, PA5471 was deleted from the mexXY-expressing pan-aminoglycoside-resistant mutants K2966 and K2968 described above and from several mexXY-expressing pan-aminoglycoside-resistant CF isolates described previously (47), and the impact on mexXY expression (Fig. 3 and 4) and aminoglycoside resistance (Table 5) was determined. Deletion of PA5471 from K2966 and K2967 abrogated the increased mexXY expression of these mutants (Fig. 3, lanes 3 and 5 [cf. lanes 2 and 4]) and concomitantly increased susceptibility to aminoglycosides, though not to the same extent as seen for the ΔmexXY derivatives of these strains or for a PA5471 knockout of K767 (K2413) (Table 4). Elimination of PA5471 from the CF isolates reduced mexXY expression to some extent in every instance but one (CF isolate K2153) (Fig. 4, compare lanes 3 and 4). Interestingly, elimination of PA5471 in K2153 also had a minimal impact on aminoglycoside susceptibility and much less than was seen when mexXY was eliminated from this isolate, in contrast to the case for the other isolates, where loss of PA5471 or mexXY had a similar impact (Table 5). Thus, PA5471 seems to be generally necessary for mexXY expression/MexXY-OprM-mediated pan-aminoglycoside resistance in lab-selected and CF isolates. Despite this, none of the aforementioned pan-aminoglycoside-resistant lab or CF isolates showed any increase in PA5471 expression or carried a mutation in the PA5471.1 ORF. This observation that PA5471 is necessary for mexXY expression and pan-aminoglycoside resistance is consistent with the observation that none of the lab/CF isolates harbored mutations in mexZ or the mexZ-mexXY promoter region; such mutations have been shown to yield mexXY expression and pan-aminoglycoside resistance independent of PA5471 (34). Indeed, in selecting mexXY-expressing pan-amino-glycoside-resistant mutants following peroxide exposure of P. aeruginosa in vitro, the only instance where mexZ mutants were recovered was when a PA5471 deletion mutant, K2413, was employed (data not shown). This argues that most mutations that yield mexXY expression and the attendant pan-aminoglycoside resistance “operate” through PA5471.
FIG. 3.

PA5471-dependent MexXY expression in pan-aminoglycoside-resistant mutants selected following peroxide exposure. Expression of mexXY was assessed in K767 (wild type; lane 1), K2966 (pan-aminoglycoside-resistant mutant; lane 2), K2973 (K2966 ΔPA5471; lane 3), K2967 (pan-aminoglycoside-resistant mutant; lane 4), and K2974 (K2967 ΔPA5471; lane 5) using RT-PCR. Expression of rpoD was also assessed and served as an internal control that ensured that equal amounts of RNA were employed in all of the RT-PCRs shown. The PCR portion of the RT-PCRs was carried out for 32 (mexX) or 20 (rpoD) cycles (upper panels) and for 34 (mexX) or 22 (rpoD) cycles (lower panels).
FIG. 4.
PA5471-dependent mexXY expression in pan-aminoglycoside-resistant CF isolates. Expression of mexXY was assessed in CF isolates and their PA5471 deletion derivatives using RT-PCR. Lane 1, K2152; lane 2, K2427 (K2152 ΔPA5471); lane 3, K2153; lane 4, K2428 (K2153ΔPA5471); lane 5, K2160; lane 6, K2430 (K2160 ΔPA5471); lane 7, K2161; lane 8, K2431 (K2161 ΔPA5471); lane 9, K2158; lane 10, K2432 (K2158 ΔPA5471); lane 11, K2163; lane 12, K2433 (K2163 ΔPA5471). Expression of rpoD was also assessed and served as an internal control that ensured that equal amounts of RNA were employed in all of the RT-PCRs shown. The PCR portion of the RT-PCRs was carried out for 32 (mexX) or 20 (rpoD) cycles (upper panels and for 34 (mexX) or 22 (rpoD) cycles (lower panels).
TABLE 5.
PA5471-dependent MexXY-mediated pan-aminoglycoside resistance in peroxide-exposed and CF isolates of P. aeruginosaa
| Strain | PA5471b | MIC (μg/ml)c |
|||
|---|---|---|---|---|---|
| AMI | TOB | GEN | PAR | ||
| K767 | + | 4 | 1 | 4 | 256 |
| K2413 | − | 1-2 | 1 | 1-2 | 16 |
| K2966d | + | 16 | 2 | 8 | >2,048 |
| K2973 | − | 4 | 1 | 2 | 128 |
| K2968d | + | 8 | 2 | 8 | 2,048 |
| K2975 | − | 2 | 1 | 2 | 128 |
| K2967d | + | 8 | 4 | 8 | 1,024 |
| K2974 | − | 2 | 1 | 2 | 32 |
| K2152e | + | 16 | 4 | 16 | 512 |
| K2427 | − | 16 (8) | 4 (4) | 8 (4) | 64 (32) |
| K2153e | + | 16 | 8 | 16 | 512 |
| K2428 | − | 8 (2) | 4 (4) | 8 (2) | 256 (32) |
| K2160e | + | 64 | 32 | 64 | 2,048 |
| K2430 | − | 32 (16) | 16 (16) | 16 (16) | 256 (64) |
| K216e | + | 32 | 16 | 64 | 2,048 |
| K2431 | − | 16 (16) | 16 (8) | 16 (8) | 128 (64) |
| K2158e | + | 32 | 16 | 32 | 1,024 |
| K2432 | − | 8 (8) | 8 (8) | 8 (8) | 128 (64) |
| K2163e | + | 16 | 8 | 16 | 128 |
| K2433 | − | 8 (8) | 8 (8) | 8 (4) | 64 (32) |
The PA5471 gene was deleted from mexXY-expressing pan-aminoglycoside-resistant (i) mutants selected on amikacin following peroxide exposure and (ii) CF isolates, and the impact on aminoglycoside susceptibility was assessed. Data for wild-type strain K767 and its ΔPA5471 derivative K2413 are shown for comparison purposes.
PA5471 status of the indicated strains. +, present; −, absent owing to deletion.
AMI, amikacin; TOB, tobramycin; GEN, gentamicin; PAR, paromomycin. Numbers in parentheses represent MICs for ΔmexXY derivatives of the various CF isolates and have been published previously (47). They are provided to permit comparison with the ΔPA5471 derivatives of those same CF isolates.
Mutant strain selected on amikacin.
Clinical CF isolate.
DISCUSSION
In vitro exposure to ROS increases the frequency with which aminoglycoside resistant mutants of P. aeruginosa are recovered, dependent upon MexXY-OprM and PA5471. It is interesting to note, however, that MexXY-OprM-dependent aminoglycoside resistance does not necessarily follow from increased mexXY expression and indeed, enhanced mexXY expression alone, as seen, for example, in mexZ deletion strain K2145, appears to be insufficient for resistance. Thus, additional genes/mutations must operate with/through MexXY-OprM to promote aminoglycoside resistance. In the lab and clinical isolates studied here, this gene(s)/mutation(s) appears to act “through” PA5471, with mexXY expression and aminoglycoside resistance being compromised in the absence of this gene. This perhaps is not surprising, given that PA5471 acts naturally to promote mexXY expression (34). While mexXY expression can occur independently of PA5471 in the case of mexZ mutants (34) and indeed mexXY-expressing aminoglycoside-resistant mexZ mutants were readily selected in this study using the PA5471-deficient mutant strain K2413, such mutants were not recovered in this study from otherwise wild-type cells, and the clinical strains studied here similarly lacked mutations in mexZ (47). Presumably, the frequency of mutations that affect mexXY expression via PA5471 is substantially higher than the mexZ mutation frequency (perhaps owing to the existence of multiple genes whose disruption affects PA5471 and mexXY expression). In this regard, and recognizing that PA5471 and mexXY are induced in response to ribosome disruption with antimicrobials, it may be that mutation of various genes linked to translation/protein synthesis can upregulate mexXY via PA5471. It has been shown, for example, that spontaneous mutations in the fmt gene, encoding a methionyl-tRNA-formyltransferase, yield increased PA5471 and mexXY expression (6), as does transposon disruption of the rplY gene, encoding a probable ribosomal protein, L25 (16). Neither of these genes, however, was mutated in the in vitro-selected mexXY-expressing pan-aminoglycoside-resistant mutants described in the current study.
While ROS are known to damage DNA and so have the potential to be mutagenic (10), the increased resistance frequency seen for peroxide-treated P. aeruginosa is not explainable by ROS-promoted mutagenesis inasmuch as its effect is lost in strains lacking PA5471. The observation, too, that PA5471 hyperexpression in the absence of peroxide provides a similar increase in aminoglycoside resistance frequency argues that ROS increase resistance frequency as a consequence of their positive impact on PA5471 expression. Their enhancement of aminoglycoside resistance frequency is not, however, explainable solely by their positive influence on mexXY expression, since this enhancement was also seen in a mexZ deletion mutant already hyperexpressing mexXY, enhancement which was also PA5471 dependent. Presumably, PA5471 expression provides a selective pressure for mutations that ultimately affect aminoglycoside susceptibility, possibly via its influences on expression of additional genes in P. aeruginosa. DNA array studies have, for example, revealed that many genes are influenced, both positively and negatively, by the PA5471 status of the cell (C. Dean, unpublished data).
Aminoglycosides have been and continue to be widely used in treating P. aeruginosa lung infections in CF (4, 42) and so undoubtedly provide some selective pressure for the development of MexXY-mediated aminoglycoside resistance. Certainly, mexXY-expressing pan-aminoglycoside-resistant mutants could be recovered in the current study from P. aeruginosa not exposed to peroxide (data not shown), in agreement with earlier studies (22). Still, this does not explain the general lack of other aminoglycoside resistance mechanisms in CF isolates (19, 45), which should be as readily selected by aminoglycosides. At the very least, ROS in the CF lung may enrich for mexXY-expressing mutants that can be selected by aminoglycosides during therapy and may provide selective pressure for maintaining such mutants during periods where antibiotics are not being used.
The positive influence of ROS on mexXY expression and MexXY-OprM-dependent aminoglycoside resistance notwithstanding, why both ROS and ribosome-targeting antimicrobials induce mexXY expression in P. aeruginosa and do so via PA5471 is uncertain. A possible explanation lies in the link between translational (in)fidelity and protein oxidation. It is known, for example, that translational fidelity is reduced in nongrowing senescent bacteria, which thus accumulate abnormal polypeptides that are prone to cell-mediated oxidation/oxidative damage, with oxidation somehow identifying these as candidates for destruction and/or removal (2, 11, 12, 13, 29). Ribosome disruption with antibiotics also leads to accumulation of abnormal polypeptides in bacteria (18, 20, 50), which may similarly be subjected to natural oxidative processes in the cell that target them for destruction or removal (possibly by MexXY-OprM). Indeed, using antibiotics or mutations to compromise ribosome function, the production of aberrant proteins that are subsequently prone to oxidation has been seen in E. coli (15). Application of an exogenous oxidative stress (e.g., with peroxide in vitro or ROS in the CF lung) will also lead to oxidation of normal polypeptides in bacteria (11, 13, 36), possibly targeting them for destruction and removal via the same mechanism (hence the common recruitment of PA5471 and, possibly, MexXY by ribosome-targeting antibiotics and ROS). It is also possible that ROS, like ribosome-targeting antimicrobials, directly disrupt ribosomes, leading to accumulation of the aberrant polypeptides that may be substrates for PA5471/MexXY. Either way, PA5471/MexXY may contribute to a natural process for removal of abnormal proteins that accumulate in response to aging and environmental stresses (including antibiotics).
Acknowledgments
This work was supported by an operating grant from the Canadian Cystic Fibrosis Foundation.
Footnotes
Published ahead of print on 20 December 2010.
REFERENCES
- 1.Ausubel, F. M., et al. 1992. Short protocols in molecular biology, 2nd ed. John Wiley & Sons, Inc., New York, NY.
- 2.Ballesteros, M., A. Fredriksson, J. Henriksson, and T. Nystrom. 2001. Bacterial senescence: protein oxidation in non-proliferating cells is dictated by the accuracy of the ribosomes. EMBO J. 20:5280-5289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Baum, E. Z., et al. 2009. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:2785-2790. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Canton, R., et al. 2005. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin. Microbiol. Infect. 11:690-703. [DOI] [PubMed] [Google Scholar]
- 5.Cao, L., R. Srikumar, and K. Poole. 2004. MexAB-OprM hyperexpression in NalC type multidrug resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719. Mol. Microbiol. 53:1423-1436. [DOI] [PubMed] [Google Scholar]
- 6.Caughlan, R. E., et al. 2009. Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression. Antimicrob. Agents Chemother. 53:5015-5021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Chang, W., D. A. Small, F. Toghrol, and W. E. Bentley. 2005. Microarray analysis of Pseudomonas aeruginosa reveals induction of pyocin genes in response to hydrogen peroxide. BMC Genomics 6:115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Chang, W., D. A. Small, F. Toghrol, and W. E. Bentley. 2005. Microarray analysis of toxicogenomic effects of peracetic acid on Pseudomonas aeruginosa. Environ. Sci. Technol. 39:5893-5899. [DOI] [PubMed] [Google Scholar]
- 9.Choi, K. H., A. Kumar, and H. P. Schweizer. 2006. A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J. Microbiol. Methods 64:391-397. [DOI] [PubMed] [Google Scholar]
- 10.Ciofu, O., B. Riis, T. Pressler, H. E. Poulsen, and N. Hoiby. 2005. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 49:2276-2282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Davies, K. J., and S. W. Lin. 1988. Degradation of oxidatively denatured proteins in Escherichia coli. Free Radic. Biol. Med. 5:215-223. [DOI] [PubMed] [Google Scholar]
- 12.Davies, K. J., and S. W. Lin. 1988. Oxidatively denatured proteins are degraded by an ATP-independent proteolytic pathway in Escherichia coli. Free Radic. Biol. Med. 5:225-236. [DOI] [PubMed] [Google Scholar]
- 13.Dean, R. T., S. Fu, R. Stocker, and M. J. Davies. 1997. Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J. 324:1-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.de Kievit, T. R., et al. 2001. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45:1761-1770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Dukan, S., et al. 2000. Protein oxidation in response to increased transcriptional or translational errors. Proc. Natl. Acad. Sci. U. S. A. 97:5746-5749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.El'Garch, F., K. Jeannot, D. Hocquet, C. Llanes-Barakat, and P. Plesiat. 2007. Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 51:1016-1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Frisk, A., et al. 2004. Transcriptome analysis of Pseudomonas aeruginosa after interaction with human airway epithelial cells. Infect. Immun. 72:5433-5438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Harms, J. M., H. Bartels, F. Schlunzen, and A. Yonath. 2003. Antibiotics acting on the translational machinery. J. Cell Sci. 116:1391-1393. [DOI] [PubMed] [Google Scholar]
- 19.Henrichfreise, B., I. Wiegand, W. Pfister, and B. Wiedemann. 2007. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob. Agents Chemother. 51:4062-4070. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Hermann, T. 2005. Drugs targeting the ribosome. Curr. Opin. Struct. Biol. 15:355-366. [DOI] [PubMed] [Google Scholar]
- 21.Hoang, T. T., R. R. Karkhoff-Schweizer, A. J. Kutchma, and H. P. Schweizer. 1998. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212:77-86. [DOI] [PubMed] [Google Scholar]
- 22.Hocquet, D., et al. 2008. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52:1173-1175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Hocquet, D., P. Nordmann, F. El Garch, L. Cabanne, and P. Plesiat. 2006. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1347-1351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Inoue, H., H. Nojima, and H. Okayama. 1990. High efficiency transformation of Escherichia coli with plasmids. Gene 96:23-28. [DOI] [PubMed] [Google Scholar]
- 25.Jacquot, J., O. Tabary, P. Le Rouzic, and A. Clement. 2008. Airway epithelial cell inflammatory signalling in cystic fibrosis. Int. J. Biochem. Cell Biol. 40:1703-1715. [DOI] [PubMed] [Google Scholar]
- 26.Jeannot, K., M. L. Sobel, F. El Garch, K. Poole, and P. Plesiat. 2005. Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction. J. Bacteriol. 187:5341-5346. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Jo, J. T., F. S. Brinkman, and R. E. Hancock. 2003. Aminoglycoside efflux in Pseudomonas aeruginosa: involvement of novel outer membrane proteins. Antimicrob. Agents Chemother. 47:1101-1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kerr, K. G., and A. M. Snelling. 2009. Pseudomonas aeruginosa: a formidable and ever-present adversary. J. Hosp. Infect. 73:338-344. [DOI] [PubMed] [Google Scholar]
- 29.Lee, Y. S., S. C. Park, A. L. Goldberg, and C. H. Chung. 1988. Protease So from Escherichia coli preferentially degrades oxidatively damaged glutamine synthetase. J. Biol. Chem. 263:6643-6646. [PubMed] [Google Scholar]
- 30.Masuda, N., and S. Ohya. 1992. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:1847-1851. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Masuda, N., et al. 2000. Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:2242-2246. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Matsuo, Y., S. Eda, N. Gotoh, E. Yoshihara, and T. Nakae. 2004. MexZ-mediated regulation of mexXY multidrug efflux pump expression in Pseudomonas aeruginosa by binding on the mexZ-mexX intergenic DNA. FEMS Microbiol. Lett. 238:23-28. [DOI] [PubMed] [Google Scholar]
- 33.Morita, Y., C. Gilmour, D. Metcalf, and K. Poole. 2009. Translational control of the antibiotic inducibility of the PA5471 gene required for mexXY multidrug efflux gene expression in Pseudomonas aeruginosa. J. Bacteriol. 191:4966-4975. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Morita, Y., M. L. Sobel, and K. Poole. 2006. Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product. J. Bacteriol. 188:1847-1855. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Moskowitz, S. M., et al. 2008. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr. Pulmonol. 43:874-881. [DOI] [PubMed] [Google Scholar]
- 36.Nishida, T., et al. 2006. Escherichia coli engineered to produce eicosapentaenoic acid becomes resistant against oxidative damages. FEBS Lett. 580:2731-2735. [DOI] [PubMed] [Google Scholar]
- 37.Pena, C., et al. 2009. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 β-lactamase. J. Clin. Microbiol. 47:2381-2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Poole, K. 2004. Efflux pumps, p. 635-674. In J.-L. Ramos (ed.), Pseudomonas, vol. I. Genomics, life style and molecular architecture. Kluwer Academic/Plenum Publishers, New York, NY. [Google Scholar]
- 39.Poole, K. 2004. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10:12-26. [DOI] [PubMed] [Google Scholar]
- 40.Poole, K. 2005. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:479-487. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Poole, K. 2005. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56:20-51. [DOI] [PubMed] [Google Scholar]
- 42.Ratjen, F., F. Brockhaus, and G. Angyalosi. 2009. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J. Cyst. Fibros. 8:361-369. [DOI] [PubMed] [Google Scholar]
- 43.Rottner, M., J. M. Freyssinet, and M. C. Martinez. 2009. Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir. Res. 10:23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- 45.Shawar, R. M., et al. 1999. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 43:2877-2880. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Simon, R., U. Priefer, and A. Puehler. 1983. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram-negative bacteria. Biotechnology 1:784-791. [Google Scholar]
- 47.Sobel, M. L., G. A. McKay, and K. Poole. 2003. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 47:3202-3207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Son, M. S., W. J. Matthews, Jr, Y. Kang, D. T. Nguyen, and T. T. Hoang. 2007. In vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients. Infect. Immun. 75:5313-5324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Taccetti, G., S. Campana, A. S. Neri, V. Boni, and F. Festini. 2008. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis. J. Chemother. 20:166-169. [DOI] [PubMed] [Google Scholar]
- 50.Thompson, J., M. O'Connor, J. A. Mills, and A. E. Dahlberg. 2002. The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J. Mol. Biol. 322:273-279. [DOI] [PubMed] [Google Scholar]
- 51.Vettoretti, L., et al. 2009. Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur. J. Clin. Microbiol. Infect. Dis. 28:1217-1222. [DOI] [PubMed] [Google Scholar]
- 52.Vettoretti, L., et al. 2009. Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 53:1987-1997. [DOI] [PMC free article] [PubMed] [Google Scholar]

